Regeneron Pharmaceuticals, Inc. (LON:0R2M)
559.00
+3.42 (0.61%)
At close: Aug 13, 2025
Regeneron Pharmaceuticals Revenue
Regeneron Pharmaceuticals had revenue of $3.68B USD in the quarter ending June 30, 2025, with 3.62% growth. This brings the company's revenue in the last twelve months to $14.21B, up 5.38% year-over-year. In the year 2024, Regeneron Pharmaceuticals had annual revenue of $14.20B with 8.27% growth.
Revenue (ttm)
$14.21B
Revenue Growth
+5.38%
P/S Ratio
4.14
Revenue / Employee
$940.96K
Employees
15,106
Market Cap
42.91B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 14.20B | 1.08B | 8.27% |
Dec 31, 2023 | 13.12B | 944.30M | 7.76% |
Dec 31, 2022 | 12.17B | -3.90B | -24.26% |
Dec 31, 2021 | 16.07B | 7.57B | 89.14% |
Dec 31, 2020 | 8.50B | 1.94B | 29.58% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
Oxford Nanopore Technologies | 183.19M |
HUTCHMED (China) | 439.54M |
Regeneron Pharmaceuticals News
- 9 days ago - Regeneron Pharmaceuticals declares $0.88 dividend - Seeking Alpha
- 9 days ago - These Analysts Increase Their Forecasts On Regeneron Pharmaceuticals After Better-Than-Expected Earnings - Benzinga
- 9 days ago - These Analysts Increase Their Forecasts On Regeneron Pharmaceuticals After Better-Than-Expected Earnings - Benzinga
- 10 days ago - Is Regeneron Pharmaceuticals Gaining or Losing Market Support? - Benzinga
- 12 days ago - Regeneron (REGN) Q2 EPS Jumps 53% - The Motley Fool
- 12 days ago - Regeneron: Rapidly Decreasing Importance Of Eylea - Seeking Alpha
- 12 days ago - Smart Money Is Betting Big In REGN Options - Benzinga
- 12 days ago - Regeneron outlines path to $17B Dupixent annual sales and initiates 10 Lynozyfic registrational trials amid robust Q2 growth - Seeking Alpha